IDEXX Laboratories Inc
NASDAQ:IDXX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
406.92
576.87
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
IDEXX Laboratories Inc
Wall Street
Price Targets
IDXX Price Targets Summary
IDEXX Laboratories Inc
According to Wall Street analysts, the average 1-year price target for
IDXX
is 499.57 USD
with a low forecast of 410.16 USD and a high forecast of 594.3 USD.
IDXX Last Price Targets
IDEXX Laboratories Inc
The latest public price target was made on Jun 24, 2024 by
Jonathan Block
from
Stifel Nicolaus
,
who expects
IDXX
stock to
rise by 23%
over the next 12 months.
You can read more about this price target by viewing
the article on TheFly.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Jonathan Block
Stifel Nicolaus
|
510
USD
Upside 23% |
6 months ago
Jun 24, 2024
|
Idexx Laboratories price target lowered to $510 from $520 at Stifel
TheFly
|
Unknown Analyst
Barclays
|
590
USD
Upside 43% |
1 year ago
Feb 8, 2023
|
Barclays Maintains Overweight on IDEXX Laboratories, Raises Price Target to $590
Benzinga
|
Unknown Analyst
J.P. Morgan
|
550
USD
Upside 33% |
1 year ago
Feb 7, 2023
|
JP Morgan Maintains Overweight on IDEXX Laboratories, Raises Price Target to $550
Benzinga
|
Unknown Analyst
Atlantic Equities
|
600
USD
Upside 45% |
1 year ago
Feb 7, 2023
|
Atlantic Equities Maintains Overweight on IDEXX Laboratories, Raises Price Target to $600
Benzinga
|
Unknown Analyst
Citigroup
|
268
USD
Downside 35% |
1 year ago
Feb 2, 2023
|
Citigroup Maintains Buy on IDEX, Lowers Price Target to $268
Benzinga
|
Unknown Analyst
Oppenheimer
|
247
USD
Downside 40% |
1 year ago
Feb 2, 2023
|
Oppenheimer Maintains Outperform on IDEX, Raises Price Target to $247
Benzinga
|
Operating Income
Forecast
Operating Income Estimate
IDEXX Laboratories Inc
For the last 8 years the
compound annual growth rate for
IDEXX Laboratories Inc's operating income is
17%.
The projected
CAGR
for the next 4 years is
9%.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is IDXX's stock price target?
Price Target
499.57
USD
According to Wall Street analysts, the average 1-year price target for
IDXX
is 499.57 USD
with a low forecast of 410.16 USD and a high forecast of 594.3 USD.
What is IDEXX Laboratories Inc's Revenue forecast?
Projected CAGR
8%
For the last 8 years the
compound annual growth rate for
IDEXX Laboratories Inc's revenue is
11%.
The projected
CAGR
for the next 4 years is
8%.
What is IDEXX Laboratories Inc's Operating Income forecast?
Projected CAGR
9%
For the last 8 years the
compound annual growth rate for
IDEXX Laboratories Inc's operating income is
17%.
The projected
CAGR
for the next 4 years is
9%.
What is IDEXX Laboratories Inc's Net Income forecast?
Projected CAGR
10%
For the last 8 years the
compound annual growth rate for
IDEXX Laboratories Inc's net income is
20%.
The projected
CAGR
for the next 4 years is
10%.
You don't have any saved screeners yet
